WaveMan
WaveMan · Company
LNAI · Lunai Bioworks Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

LNAI Lunai Bioworks (LNAI) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001527728
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
5
13F, latest reported quarter

Lunai Bioworks insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Lunai Bioworks Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing

no insider purchases or sales on record

0 transactions on record
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
5 funds bought in last quarter
below 95% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
3.8% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 64% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch LNAI

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

Who owns LNAI: institutional holders (13F)

13F holdings, latest reported quarter
Ground Swell Capital, LLC
53,211 sh
$174.0K
STATE STREET CORP
37,537 sh
$122.7K
GEODE CAPITAL MANAGEMENT, LLC
24,156 sh
$79.0K
JANE STREET GROUP, LLC
23,683 sh
$77.4K
VANGUARD CAPITAL MANAGEMENT LLC
16,081 sh
$52.6K

Congress trades in LNAI

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

LNAI planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

LNAI mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$41.2K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$39.4K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$3.6K position · as of 2026-05-31
0.0%
Knights of Columbus U.S. ALL CAP INDEX FUND
$45 position · as of 2026-07-31
0.0%
Fidelity Series Total Market Index Fund
$5.4K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$5.8K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 5 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

LNAI financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-43.96x
TTM operating cash flow over current debt only, 2017-12-31 (103 months older than the period end)
Return on equity
n/a
average equity is zero or negative
Return on assets
-39.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on capital employed
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
P/E, trailing
n/a
no close on file at or before the as-of date
Enterprise value
n/a
no close on file at or before the as-of date
FCF yield
n/a
no close on file at or before the as-of date
PEG, trailing
n/a
no close on file at or before the as-of date
Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2026-062025-062024-062023-06
Revenue$52.0Kn/an/an/a
Operating income-$8.7M-$189.0M-$81.6M-$38.6M
Net income-$3.6M-$178.0M-$88.4M-$39.7M
EPS (diluted)-1.06-86.27-0.91-0.71
Operating cash flow-$5.3M-$7.9M-$11.0M-$11.8M
Cash$1.7M$92.7K$220.5K$1.9M
SEC XBRL, fiscal years, as known on 2026-10-28

LNAI Stock Sonar score 3/7 axes

Find similar shapesCompare

LNAI ranks highest on risk and compliance (49th percentile) and financial health (13th), and lowest on institutional and government (3rd), among Pharma & Biotech peers.

Financial health
13
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-43.96x · 13 pct, sector of 371
Institutional and government
3
Inputs
  • Funds adding, latest quarter5 · 5 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$20K · 2 pct, sector of 133
Risk and compliance
49
Inputs
  • Short interest, % of float+3.8% · 64 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+13.9% · 33 pct, sector of 511
4 not measured: Profitability, Growth, Insider conviction, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; the filed year and its quarters do not reconcile, so the trailing figure is withheld
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies